MedTrace Logo

Efficacy and Tolerability of Sensoril® in Improving Immunity and Thereby Reducing Incidence of Upper Respiratory Tract Infections

NCT04733924 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2021-10-19

No results posted yet for this study

Summary

to assess the efficacy and safety of a standardized Withania somnifera extract (Sensoril®) as an immunomodulator in individuals suffering from recurrent URTIs. The study population will be administered with this unique blend of WS extract for 12 weeks and will be assessed as per the study designated efficacy and safety variables.

Conditions

  • Immune Health

Interventions

OTHER

Aqueous extract of roots plus leaves of Withania somnifera 125 mg

One capsule before breakfast for 84 days

OTHER

Aqueous extract of roots plus leaves of Withania somnifera 250 mg

One capsule before breakfast for 84 days

OTHER

Microcrystalline Cellulose

One capsule before breakfast for 84 days

Sponsors & Collaborators

  • Vedic Lifesciences Pvt. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-21
Primary Completion
2021-04-29
Completion
2021-09-23

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04733924 on ClinicalTrials.gov